期刊文献+

肌红蛋白在非小细胞肺癌组织中的表达及临床价值

下载PDF
导出
摘要 目的探讨肌红蛋白(Mb)mRNA在非小细胞肺癌(NSCLC)组织中的表达情况及临床价值。方法NSCLC患者癌组织标本57例,同时收集其对应的癌旁组织。采用实时荧光定量PCR检测MbmRNA的方法,以GAPDH为内参基因,通过计算2-△△CT,判断NSCLC癌组织与癌旁组织的mRNA表达差异。同时分析MbmRNA表达水平与NSCLC病理类型、组织分化、临床分期、淋巴结转移等的相关性。结果成功建立实时荧光定量PCR检测MbmRNA的方法;NSCLC癌组织MbmRNA表达水平明显高于其癌旁组织(P〈0.05)。MbmRNA表达水平与病理类型、肿瘤临床分期、淋巴结转移、组织分化程度、是否吸烟等差异无统计学意义(P〉0.05);而在不同性别中差异有统计学意义,女性MbmRNA表达水平高于男性(P〈0.05)。肿瘤体积越大,MbmRNA表达水平越高。结论MbmRNA在NSCLC中出现明显上调,可能在NSCLC的发病机制起重作用。 Objective To analyze the expression and clinical value of Myoglobin ( Mb ) mRNA in non-small cell lung cancer ( NSCLC ) tissue. Methods We collected 57 cases of NSCLC tissue specimens and corresponding adjacent tissues in the First Affiliated Hospital of Wenzhou Medical University from July 2013 to February 2014. We established the real-time quantitative PCR method to detect Mb mRNA, GAPDH as reference gene, with calculating the 2-△△CT, to determine different expression of adjacent Mb NSCLC and cancer tissue. Otherwise, we analyzed the correlation of tissue Mb mRNA with NSCLC to histological type, histological grade, clinical stage, lymph node metastasis and other clinical data. Results We successfully establishedreal-time PCR method for detecting Mb mRNA; Mb mRNA expression levels of NSCLC tissues were significantly higher than its adjacent tissues (P〈0.05) . The expression of Mb mRNA wasno relative to clinical stage, lymph node metastasis, histological type, histological grade, and smoking ( P〉0.05 ) . The expression levels of Mb mRNA was significant in different gender, the expression levels of women higher than men ( P〈0.05 ) . Tumor volume was higher, Mb mRNA expressed higher. Conclusion The expression of Mb significantly increases in NSCLC and it may play an important role in the pathogenesis of NSCLC.
出处 《浙江临床医学》 2015年第9期1460-1461,1464,共3页 Zhejiang Clinical Medical Journal
基金 浙江省温州市科技局项目资助(Y20110041)
关键词 非小细胞肺癌 缺氧 肌红蛋白 MRNA Non-small cell lung cancer ( NSCLC ) Hypoxia Myoglobin ( Mb ) mRNA
  • 相关文献

参考文献13

  • 1支修益.我国肺癌流行病学现状分析[J].中国处方药,2009(2):56-57. 被引量:99
  • 2Martinet Y,HirschFR,Martinet N, et al. Clinical and biological basis of lung cancer prevention. Birka user,Basel,1998.297-304.
  • 3Custodio A, M 6 ndez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and furore implications. Cancer Treat Rev,2012,38(1):36-53.
  • 4Brunori M, Bourgeois D, Vallone B, et al. The structural dynamics of . myoglobin. J Struct Biol, 2004,147(3):223-234.
  • 5Wittenberg JB, Wittenberg BA. Myoglobin function reassessed. J Exp Bio1,2003,206:2011-2020.
  • 6Brahimi-Hom, M.C, Chiche, J, Pouyss 6 gur, J. Hypoxia and cancer. J. Mol. Med,2007,85(12):1301-1307.
  • 7Join, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Scierlce,2005,307(5706):58-62.
  • 8Harris, A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer,2002,2(1) :38-47.
  • 9Brooks JJ. Immunohistochernistry of soft tissue tumors. Myoglobin as a tumor marker for rhabdomyosarcoma. Cancer, 1982,50(9):1757-1763.
  • 10Carda C, Ferrer J,Vilanova M, et al. Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch,2005,446(1 ) :46-51.

共引文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部